波兰专门用于COVID-19患者的重症监护病房的呼吸机相关肺炎
Marta Wałaszek1, Piotr Serwacki2, Zbigniew Cholewa2
1University of Applied Sciences in Tarnów, ul. Mickiewicza 8, Tarnów, 33-100, Poland.
BMC pulmonary medicine
|November 17, 2023
概括
与非COVID-19患者相比,在重症监护室 (ICU) 的COVID-19患者患呼吸机相关肺炎 (VAP) 的风险是COVID-19患者的两倍. 在这个队列中,Acinetobacter baumannii是最常见的VAP病因.
科学领域:
- 传染性疾病 传染性疾病
- 临界护理医学 临界护理医学
- 流行病学 流行病学
背景情况:
- 医疗相关感染 (HAI) 是重症监护室 (ICU) 的一个重要问题.
- 冠状病毒疾病2019 (COVID-19) 疫情使许多患者需要接受ICU治疗.
- 了解大流行期间在ICU设置中的HAI流行病学至关重要.
研究的目的:
- 追溯评估ICU患者中HAI的流行病学.
- 为了比较COVID-19和非COVID-19患者之间的HAI率.
- 在ICU环境中识别与HAI相关的风险因素和常见病原体.
主要方法:
- 在2020年至2021年期间,在波兰南部进行了一项病例控制研究.
- 分析了416名ICU患者 (125名COVID-19,291名非COVID-19) 的数据.
- 医疗保健相关感染监测网络 (HAI-Net) 标准用于诊断.
主要成果:
- 在COVID-19患者中,死亡率显著上升 (64%对16%).
- 呼吸器相关肺炎 (VAP) 的发生率在COVID-19患者中较高 (14.1/1000个患者日 vs 3.6/1000个患者日).
- 在VAP病例中,Acinetobacter baumannii是最常见的病原体,特别是在COVID-19患者中 (18.2%对4.4%).
结论:
- 在ICU中的COVID-19患者面临高风险的VAP.
- 这项研究强调了Acinetobacter baumannii作为ICU获得的VAP中的关键病原体.
- 这些发现强调了在流行病期间需要在ICU中制定有针对性的感染控制策略.
相关概念视频
Pneumonia I: Introduction
246
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
246
Mechanical Ventilation II: Invasive Ventilation
154
Ventilators are essential medical equipment used to aid patients with respiratory difficulties. Their primary function is to assist or replace spontaneous breathing by providing mechanical ventilation. There are two general classes of mechanical ventilators: negative-pressure and positive-pressure ventilators.
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...
154
Pneumonia III: Complications and Assessment
240
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
240
Pneumonia IV: Management
337
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
337
Acute Respiratory Failure-II
243
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
243
Acute Respiratory Failure-III
187
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
187


